Mutant KRAS Program

About Atommap

Atommap is a private, pre-clinical stage biotech company pioneering a computational approach to drug discovery centered on simulating and harnessing the dynamic motion of proteins. Its proprietary platform integrates molecular dynamics, generative AI, and predictive computational assays to design novel therapeutic modalities, particularly molecular glues and targeted protein degraders, for historically undruggable targets. Founded by veterans from D. E. Shaw Research, Schrödinger, and Silicon Therapeutics, the company is advancing a pipeline in oncology, exemplified by case studies on mutant KRAS and SMARCA2.

Therapeutic Areas